Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in Chinese Advanced ALK+ NSCLC
NCT06092086Phase 2Recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started Aug 2023; status: recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06092086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092086.